News | March 10, 2015

Acute Myocardial Infarction Patient Treated with New Mechanical Thrombectomy Device

Aspire system removes thrombus occluding blood vessel in coronary arteries

Aspire, Control Medical, thrombectomy, atherectomy devices, cath lab

March 10, 2015 —George Adams, M.D., an interventional cardiologist with North Carolina Heart and Vascular, successfully treated a patient having an acute myocardial infarction (AMI) with the Aspire Mechanical Thrombectomy System.

The patient presented with chest pain, nausea and shortness of breath. An angiogram was performed and showed a long segment of thrombus occluding the ramus intermedius, a blood vessel in the coronary arteries. Adams used the Aspire Mechanical Thrombectomy device to remove the thrombus, and then he was able to angioplasty and stent the artery, relieving the patient from his symptoms.

"When a patient is having an AMI, removing the thrombus in the symptomatic artery is important," said Adams. "The Aspire device allows me to remove the thrombus quickly, helping to relieve the patients symptoms."

The Aspire System allows clinicians to instantly start, stop, increase, decrease, pulse or maintain thrombectomy force during the procedure. Aspire Mechanical Aspirators also aspirate up to 280ml, almost 10 times more than basic syringe systems, without multiple messy and time-consuming catheter connections, disconnections and re-connections.

The patented Aspire RX-LP6 Mechanical Thrombectomy System includes an Aspire Mechanical Aspirator (drive unit/pump) and a low-profile rapid-exchange (RX) thrombectomy catheter. Mechanical aspirators are also available alone and may be connected to any thrombectomy catheter the clinician chooses to use. Control Medical also manufactures Aspire Max Mechanical Thrombectomy Systems with larger over-the-wire (OTW) thrombectomy catheters for use in the peripheral vasculature.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init